HealthcareServices

Kidney Transplant Rejection Market Outlook 2026–2030: Key Business Drivers and Trends

March 4, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the kidney transplant rejection market from 2026–2035 with trusted insights from The Business Research Company

What is the estimated market size of the Kidney Transplant Rejection Market by the end of 2030?

The kidney transplant rejection market has experienced substantial expansion in recent years. This market is projected to expand from $3.51 billion in 2025 to $3.76 billion in 2026, at a compound annual growth rate (CAGR) of 7.2%. The growth observed historically can be credited to an increase in kidney transplant procedures, advancements in histopathological assessment techniques, greater availability of immunosuppressive drugs, the expansion of transplant center networks, and enhanced post-transplant patient survival rates.

The kidney transplant rejection market is poised for significant expansion in the coming years, with projections indicating a growth to $5.01 billion by 2030, reflecting a compound annual growth rate (CAGR) of 7.4%. This anticipated growth can be linked to a surging demand for personalized immunosuppression strategies, the wider embrace of molecular diagnostics, the progression of precision medicine in transplant care, an increasing emphasis on ensuring long-term graft survival, and greater investment in transplant monitoring technologies. Notable trends expected in this period include the rising adoption of biomarker-based rejection monitoring, an increased reliance on genomics-based diagnostic approaches, ongoing optimization of immunosuppressive therapy protocols, the spread of non-invasive rejection surveillance methods, and an intensified focus on the early detection of chronic rejection.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=33190&type=smp

What Drivers Are Shaping Future Opportunities In The Kidney Transplant Rejection Market?

The increasing occurrence of end-stage renal disease is projected to fuel the expansion of the kidney transplant rejection market moving forward. End-stage renal disease (ESRD) signifies the ultimate, irreversible phase of chronic kidney disease where kidneys fail to perform sufficiently without either dialysis or a kidney transplant. The incidence of ESRD is escalating due to the rising rates of chronic conditions like diabetes and hypertension, which gradually damage the kidneys, leading to failure. Kidney transplant rejection mandates advanced monitoring and therapeutic interventions, directly supporting the management of end-stage renal disease by ensuring transplanted kidneys stay functional and patients maintain kidney health. For instance, in September 2024, data from the National Institute of Diabetes and Digestive and Kidney Diseases, a US-based government institute, indicated that in 2023, more than 808,000 individuals in the United States were living with end-stage kidney disease (ESKD), also known as end-stage renal disease (ESRD), with 68% receiving dialysis and 32% having undergone a kidney transplant. Therefore, the growing incidence of end-stage renal disease is stimulating the growth of the kidney transplant rejection market.

Which Segment Groups Are Influencing The Kidney Transplant Rejection Market?

The kidney transplant rejection market covered in this report is segmented –

1) By Rejection Type: Chronic Rejection; Acute Rejection

2) By Treatment: Immunosuppressive Drugs; Antibody-Mediated Rejection Therapies

3) By Diagnostic Approach: Biomarker-Based Diagnostics; Genomics-Based Diagnostics

4) By Therapeutics: Small Molecule Inhibitors; Biologic Therapies

5) By End-Users: Transplant Centers Or Hospitals; Diagnostic Laboratories; Pharmacies

Subsegments:

1) By Chronic Rejection: Antibody Mediated Chronic Rejection; Chronic Allograft Nephropathy; Interstitial Fibrosis And Tubular Atrophy; Vascular Chronic Rejection; Mixed Chronic Rejection

2) By Acute Rejection: Cellular Acute Rejection; Antibody Mediated Acute Rejection; Hyperacute Rejection; Mixed Acute Rejection; Vascular Acute Rejection

How Are New Market Trends Shaping The Landscape Of The Kidney Transplant Rejection Market?

Leading companies operating within the kidney transplant rejection market are concentrating on developing advanced diagnostic solutions, such as noninvasive urinary biomarker testing, to facilitate faster, safer, and more accurate identification of transplant rejection. This noninvasive urinary biomarker testing involves analyzing urine samples to detect molecular indicators of kidney inflammation or rejection, thereby enabling clinicians to identify transplant complications swiftly and safely without requiring invasive biopsies. For instance, in May 2024, Thermo Fisher Scientific Inc., a US-based biotechnology company, introduced its CXCL10 testing service, a novel diagnostic tool for kidney transplant recipients. The CXCL10 test identifies the CXCL10 chemokine in urine, which is linked to early transplant rejection and inflammation. It delivers results within 24 hours, promoting quicker clinical decisions, reducing the necessity for unnecessary biopsies, and enhancing patient convenience by employing noninvasive sample collection. Developed and validated by Thermo Fisher’s One Lambda Laboratories, the assay integrates high sensitivity and specificity with ease of use in clinical settings, ultimately supporting improved post-transplant care and patient outcomes.

Who Are The Major Companies Operating In The Kidney Transplant Rejection Market?

Major companies operating in the kidney transplant rejection market are F. Hoffmann-La Roche AG, Merck & Co. Inc., Sanofi SA, Novartis AG, Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., Takeda Pharmaceutical Company Limited, Amgen Inc., Asahi Kasei Corporation, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Biogen Inc., ChugAI Pharmaceutical Co. Ltd., Eurofins Scientific SE, Illumina Inc., Natera Inc., CareDx Inc., Azurity Pharmaceuticals Inc., Insight Molecular Diagnostics, and RenalytixAI plc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/kidney-transplant-rejection-market-report

Which Region Is Anticipated To See The Fastest Growth In The Kidney Transplant Rejection Market?

North America was the largest region in the kidney transplant rejection market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the kidney transplant rejection market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Kidney Transplant Rejection Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=33190&type=smp

Browse Through More Reports Similar to the Global Kidney Transplant Rejection Market 2026, By The Business Research Company

Kidney Transplant Market Report 2026

https://www.thebusinessresearchcompany.com/report/kidney-transplant-global-market-report

Organ Transplant Immunosuppressant Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/organ-transplant-immunosuppressant-drugs-global-market-report

Continuous Renal Replacement Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/continuous-renal-replacement-therapy-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795